GlassScriptPhysician profile
Luis Ortiz Espinosa
NPI 1053390732
$18,490.55
in general payments reported to CMS, 2019-2025
19 companies · $3,564 in 2025
The $3,564 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,255 · 2020: $2,132 · 2021: $838 · 2022: $3,093 · 2023: $1,480 · 2024: $2,128 · 2025: $3,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,419 · Consulting Fee: $1,488 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,418.86 |
| Consulting Fee | $1,487.50 |
| Education | $265.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,953.47 | 2019-2025 | Skyrizi |
| Pfizer Pharmaceuticals LLC | $4,261.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $2,548.62 | 2022-2025 | Sotyktu |
| Janssen Pharmaceuticals, INC | $726.78 | 2019-2025 | Tremfya |
| Janssen Biotech, INC. | $686.89 | 2019-2025 | Tremfya |
| Allergan, INC. | $482.41 | 2019-2022 | |
| Pbg Puerto Rico LLC | $455.55 | 2019-2025 | |
| Genzyme Corporation | $431.26 | 2019-2024 | |
| Revance Therapeutics, INC. | $231.40 | 2024-2025 | Daxxify |
| Eli Lilly Export S.A. Puerto Rico Branch | $169.85 | 2024-2025 | Ebglyss |
| Amgen INC. | $162.00 | 2021-2024 | Otezla, Amjevita |
| Strata Skin Sciences, INC. | $130.93 | 2021-2025 | Xtrac |
| Galderma Laboratories, L.P. | $61.06 | 2019-2025 | |
| Leo Pharma INC. | $53.34 | 2022 | |
| Pfizer INC. | $50.22 | 2021-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.68 | 2023 | |
| Sanofi-Aventis U.S. LLC | $23.00 | 2021 | |
| Genentech USA, INC. | $21.95 | 2022 | |
| Verity Pharmaceuticals INC. | $15.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Ortiz Espinosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.